-
2026 EHA Academic Feast: Multiple Myeloma Treatment Enters a New Era of Precision Stratification—From Reshaping ASCT Status to Breaking the Deadlock in Ultra-High Risk Strategies
In June 2026 local time, the European Hematology Association (EHA) Annual Congress was grandly held. In the Multiple Myeloma (MM) session, top global hematology experts engaged in in-depth dialogues regarding the treatment pathways for newly diagnosed multiple myeloma (NDMM), liquid biopsy for prognostic assessment, and intensified treatment regimens for ultra-high risk patients. This session was…
-
EHA Echoes · Voices from China | Prof. Meng Lü: CAR-T vs Antibody-Based Therapy as a Bridge to Transplantation—Defining the Optimal Stratified Approach for R/R B-ALL
In the era of rapidly evolving immunotherapy, determining the optimal bridging strategy to hematopoietic stem cell transplantation (HSCT) for patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) remains a major clinical challenge. At EHA 2026, Prof. Meng Lü and colleagues from Peking University People’s Hospital presented an important oral study based on a large…
-
EHA Insights | Prof. Shenmiao Yang: Toward a Cure—New Strategies in CLL Through Targeted Combination Therapy
As targeted therapies continue to transform the treatment landscape of chronic lymphocytic leukemia (CLL), therapeutic goals are evolving beyond long-term disease control toward deeper remissions, fixed-duration treatment strategies, and even the possibility of functional cure. At EHA 2026, several landmark studies provided important evidence supporting this paradigm shift.
-
Predicting a 92% pCR: Preoperative Radiotherapy Acts as an “Immune Primer” for High-Risk TNBC in the TBCRC-053 Trial
the field of breast cancer, Triple-Negative Breast Cancer (TNBC) has become a clinical challenge due to its high aggressiveness and lack of effective targets. Although the KEYNOTE-522 study established the standard status of Immune Checkpoint Inhibitors (ICI) combined with chemotherapy in perioperative TNBC, high-risk patients with lymph node-positive and T3/T4 stage disease still face a…
-
Breaking the Dilemma of Margins in Breast-Conserving Surgery: SHAVE Series Research Confirms CSM Significantly Reduces Re-excision Rates, but Long-term Survival Benefit Remains Dominated by Radiotherapy
At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Professor Anees B. Chagpar, a Professor of Surgery at the Yale School of Medicine, delivered an important special report titled “Does resection of cavity shave margins impact survival in breast cancer patients?”. Based on the famous SHAVE and SHAVE2 randomized controlled trials, the report…
-
EHA Reflections | Dr. Jing Pan: Novel Nanobody-Based Dual-Epitope CD5 CAR-T Uses Speed to Redefine T-ALL Immunotherapy
Treatment options remain extremely limited for patients with relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL) who relapse after CD7 CAR-T therapy. Although previous studies of humanized CD5 CAR-T cells demonstrated encouraging antitumor activity, long-term follow-up revealed a significant safety challenge: a high incidence of severe and sometimes fatal infections.
-
EHA Reflections | Professors Huilai Zhang and Junlei Jia: Decoding the Biological Landscape of Primary Breast DLBCL to Advance Precision Risk Stratification and Long-Term Disease Management
Primary breast diffuse large B-cell lymphoma (PB-DLBCL) is a rare extranodal subtype of DLBCL characterized by unique clinicopathological features and an increased risk of central nervous system (CNS) relapse. Due to its low incidence, comprehensive investigations into its biological characteristics have remained limited.
-
EHA Reflections | Professor Fengkui Zhang: Oral Factor B Inhibitor Shows Superior Efficacy and May Redefine First-Line Treatment for PNH
Complement C5 inhibitors have transformed the management of paroxysmal nocturnal hemoglobinuria (PNH) and remain the current standard first-line therapy. However, despite effective control of intravascular hemolysis, many patients continue to experience persistent anemia, limited hemoglobin recovery, and clinically significant extravascular hemolysis, leaving substantial unmet medical needs.
Connecting Medical Expertise through Media